Genetically engineered mouse models and human osteosarcoma
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is the most common form of bone cancer. Pivotal insight into the genes involved in human osteosarcoma has been provided by the study of rare familial cancer predisposition syndromes. Three kindreds stand out as predisposing to the development of osteosarcoma: Li-Fraumeni syndrome, familial retinoblastoma and RecQ helicase disorders, which include Rothmund-Thomson Syndrome in particular. These disorders have highlighted the important roles of P53 and RB respectively, in the development of osteosarcoma. The association of OS with RECQL4 mutations is apparent but the relevance of this to OS is uncertain as mutations in RECQL4 are not found in sporadic OS. Application of the knowledge or mutations of P53 and RB in familial and sporadic OS has enabled the development of tractable, highly penetrant murine models of OS. These models share many of the cardinal features associated with human osteosarcoma including, importantly, a high incidence of spontaneous metastasis. The recent development of these models has been a significant advance for efforts to improve our understanding of the genetics of human OS and, more critically, to provide a high-throughput genetically modifiable platform for preclinical evaluation of new therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 1×
“However, neither p107 nor p130 mice (or compound mutants that are viable) have a reported susceptibility to OS and these genes are not frequently mutated in human cancers based on data available through the COSMIC database [54].”
BackgroundMirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
p14ARF links the tumour suppressors RB and p53
Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., & Vousden, K. H. (1998) · Nature · doi:10.1038/25867 · Cited by 918
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24320 · Cited by 791
Linking functional decline of telomeres, mitochondria and stem cells during ageing
Sahin, E., & DePinho, R. A. (2010) · Nature · doi:10.1038/nature08982 · Cited by 759 · cited 1×
“This includes germline & conditional knockouts, alleles bearing point mutations and tissue/region-specific gene expression [171,172].”
Backgroundtwist is a potential oncogene that inhibits apoptosis
Maestro, R., Tos, A. P. D., Hamamori, Y., Krasnokutsky, S., Sartorelli, V., Kedes, L., Doglioni, C., Beach, D. H., & Hannon, G. J. (1999) · Genes & Development · doi:10.1101/gad.13.17.2207 · Cited by 516
The pediatric preclinical testing program: Description of models and early testing results
Houghton, P. J., Morton, C. L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E. A., Zhang, W., Lock, R., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21078 · Cited by 480
Essential role of limiting telomeres in the pathogenesis of Werner syndrome
Chang, S., Multani, A. S., Cabrera, N. G., Naylor, M. L., Laud, P., Lombard, D., Pathak, S., Guarente, L., & DePinho, R. A. (2004) · Nature Genetics · doi:10.1038/ng1389 · Cited by 462 · cited 1×
“However, its strongest link to OS was evident when WRN and Telomerase RNA Component (Terc) deficiency were combined in mice, with 50% of these mice developing OS [89].”
Background
Cited by
Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?
Mutsaers, A. J., & Walkley, C. R. (2014) · Bone · doi:10.1016/j.bone.2014.02.003 · Cited by 233
Self-citationToward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
Khanna, C., Fan, T. M., Gorlick, R., Helman, L. J., Kleinerman, E. S., Adamson, P. C., Houghton, P. J., Tap, W. D., Welch, D. R., Steeg, P. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2574 · Cited by 178
Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma
Liu, T., Shen, J. K., Li, Z., Choy, E., Hornicek, F. J., & Duan, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.030 · Cited by 30
Murine Models of Bone Sarcomas
Jacques, C., Renema, N., Ory, B., Walkley, C. R., Grigoriadis, A. E., & Heymann, D. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8997-3_18 · Cited by 14
Self-citation
Metadata
- Authors
- Ng, A. J., Mutsaers, A. J., Baker, E. K., & Walkley, C. R.
- Venue
- Clinical Sarcoma Research
- Published
- 2012-10-04
- Volume
- 2
- Issue
- 1
- Pages
- 19-19
- ISSN
- 2045-3329 (ISSN-L)
- OpenAlex
- W2168808367
- Cited by
- 45
- References
- 25
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetically engineered mouse models and human osteosarcoma. https://app.cochat.ai/papers/10.1186/2045-3329-2-19
- The paper
- Ng, A. J., Mutsaers, A. J., Baker, E. K., & Walkley, C. R. (2012). Genetically engineered mouse models and human osteosarcoma. Clinical Sarcoma Research. https://doi.org/10.1186/2045-3329-2-19
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.